James Robert Prudent

USPTO Granted Patents = 42 (Patent Applications = 8)

CIPO Patents = 4

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 4.8

ph-index = 20

Forward Citations = 2,411(Granted Patents)

Company Filing History:

22 out of 102

Third Wave Technologies, Inc.

patents

9 out of 11

Eragen Biosciences, Inc.

Years Active: 1998-2020

Loading Chart...

42 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10675352 - Extracellular targeted drug conjugates (2020-06-09),

2. 10240189 - Solid support assay systems and methods utilizing non-standard bases (2019-03-26),

3. 9611509 - Materials and methods for detection of nucleic acids (2017-04-04),

4. 9364554 - Extracellular targeted drug conjugates (2016-06-14),

5. 8969047 - Solid support assay systems and methods utilizing non-standard bases (2015-03-03),

6. 8703723 - Glycoside compounds and pharmaceutical compositions thereof (2014-04-22),

7. 8519117 - Materials and methods for detection of nucleic acids (2013-08-27),

8. 8518671 - Solid support assay systems and methods utilizing non-standard bases (2013-08-27),

9. 8470980 - Extracellular targeted drug conjugates (2013-06-25),

10. 8361973 - Glycoside compounds and pharmaceutical compositions thereof (2013-01-29),

11. 8313932 - Polymerase inhibitor and method of using same (2012-11-20),

12. 8217160 - Solid support assay systems and methods utilizing non-standard bases (2012-07-10),

13. 7892796 - Solid support assay systems and methods utilizing non-standard bases (2011-02-22),

14. 7829314 - Cleavage of nucleic acids (2010-11-09),

15. 7824862 - Methods for analyzing nucleic acid (2010-11-02),

Title: James Robert Prudent: A Pioneer in Drug Conjugates and Assay Systems

Introduction

James Robert Prudent, based in Madison, Wisconsin, has made significant contributions to the field of biochemistry and pharmaceuticals through his impressive portfolio of 42 patents. His innovations primarily focus on targeted drug delivery systems and advanced assay methodologies, showcasing his dedication to improving healthcare solutions.

Latest Patents

Among his latest patents, Prudent has developed extracellular drug conjugates (EDCs) that specifically target CD38, which are instrumental in treating diseases such as cancer and immune disorders, including asthma. Additionally, he has created solid support assay systems that utilize non-standard bases. This innovative approach involves attaching a capture oligonucleotide to a solid support, allowing it to hybridize with a target sequence. These methodologies often incorporate non-standard bases, achieving precise and complementary reactions crucial for modern assays.

Career Highlights

Prudent's career includes influential roles at Third Wave Technologies, Inc. and Eragen Biosciences, Inc. His work in these companies has been pivotal in advancing the understanding and application of biochemical assays and drug formulations. His patents reflect a commitment to addressing complex medical challenges through scientific innovation.

Collaborations

Throughout his career, James Robert Prudent has collaborated with notable scientists such as Victor I. Lyamichev and James E. Dahlberg. These collaborations have significantly enhanced the impact and reach of his research, fostering a collaborative environment that promotes innovation and development in the biotech field.

Conclusion

James Robert Prudent stands out as an accomplished inventor whose work in innovative drug conjugates and assay systems has the potential to transform therapeutic strategies. His impressive patent portfolio underscores his role as a leader in scientific advancements, contributing to improved health outcomes.

This text is generated by artificial intelligence and may not be accurate.